Abstract: A flame-retardant agent composition containing an organophosphorous compound represented by the general formula (I): wherein R1 and R2 each independently represent an alkyl group having 1 to 5 carbon atoms; R3 and R4 each independently represent a hydrogen atom or an alkyl group having 1 to 5 carbon atoms; Y represents a bond or a group —CH2—, —C(CH3)2—, —S—, —SO2—, —O—, —CO— or —N?N—; k represents 0 or 1; and m represents an integer of 0 to 4 and having a property such that a content of a compound represented by the formula (II): wherein R1, R2 and R3 are as defined in the general formula (I) is 1.8% by area or less when the organophosphorous compound is determined by gel permeation chromatography (GPC).

Abstract: There is provided a novel pyrrolidine derivative represented by the formula (I) or a salt thereof having an excellent DPP-IV inhibitory activity and an excellent pharmacokinetic. On the basis of the action as such, the compound of the present invention is useful for treatment and/or prevention of insulin-dependent diabetes mellitus (type 1 diabetes mellitus) and particularly for non insulin-dependent diabetes mellitus (type 2 diabetes mellitus), insulin-resistant diseases, obesity, etc. [In the formula, -A- is a single bond, —O—, —S—, —NH— or —N(lower alkyl)-; and —B is lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, non-aromatic hetero ring or aromatic hetero ring and each of those groups may be substituted.

Abstract: Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.

Abstract: Development of a host cell capable of producing a glycoprotein composition such as an antibody composition which is useful in development of medicaments is desired. The present invention provides a cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium and a process for producing a glycoprotein composition using the cell.

Abstract: Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.

Abstract: Disclosing a method for screening a protein interactive with PPAR in a ligand-dependent manner, works as a useful tool for screening a drug ameliorating insulin resistance. By the method, ECHLP as a main action ligand-dependent PPAR binding molecule, FLJ13111 as a main action ligand-selective factor interactive with PPAR? and AOP2 as an adverse action ligand-dependent PPAR binding molecule were obtained. By using ECHLP interactive with PPAR, FLJ13111 interactive with PPAR and AOP2 interactive with PPAR, a screening system for a drug ameliorating insulin resistance is constructed and disclosed, the drug giving selectively the main action with no occurrence of the adverse action.

Abstract: The present invention provides an antibody composition which specifically binds to CD20 and comprises an antibody molecule which has complex N-glycoside-linked sugar chains bound to the Fc region; a process for producing the antibody composition; and a medicament comprising the antibody composition.